Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"


CytoVale is pioneering a new class of biomarkers. Disease states dramatically alter cells’ mechanical properties through changes in nuclear and cytoskeletal structure. Until now, it has been impossible to measure these changes quickly and reliably enough to translate basic research observations into clinical utility. Using microfluidics, CytoVale can measure >10 biophysical cell markers at rates higher than 2000 cells/second, providing a high throughput, low-cost method of detecting disease.

This Mechanomics Platform, consisting of a benchtop instrument and disposable disease-specific sample cartridges, has been academically validated with clinical samples in the laboratory of co-founder (and UCLA Professor) Dino Di Carlo and published in Proceedings of the National Academy of Sciences. Commercialization is driven by co-founder and CEO Ajay Shah, a successful entrepreneur and an expert in cell-based diagnostics, and Mara MacDonald, a Harvard-trained scientist with a background in venture capital.


All NetScientific Investments – Microfluidics

Management Team

Ajay Shah, CEO

Company HQ

San Francisco, CA, USA



Cytovale - NetScientific